EGFR and fibrosarcoma: Recently, preclinical studies combining EGFR blockade with either mTOR or STAT blockade overcame resistance to anti-EGFR monotherapy in EGFR-expressing soft tissue sarcomas and in fibrosarcoma cell line [19, 40].